Compare Novartis AG (NVS) vs Skyworks Solutions Inc (SWKS) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Skyworks Solutions (SWKS) trades at $75.38, up 1.84% with bullish technical signals from moving averages. The stock shows strong earnings momentum with three consecutive quarterly beats, though revenue has declined from $5.5B in 2022 to $4.1B in 2025. Analyst consensus is positive with 58% buy ratings, though the current price exceeds the $66.44 consensus target. Recent institutional buying and conference participation indicate ongoing investor interest despite margin compression and revenue headwinds.

The outlook remains cautiously optimistic with AI data center growth providing upside potential, but investors face risks from declining profitability margins and ongoing revenue contraction. The stock's elevated P/E ratio of 39.06 requires continued earnings growth justification, while technical indicators show potential resistance near $76-77 levels.